Neurocrine Biosciences, Inc. (NBIX)
USD 109.68
(2.9%)
USD 109.68
(2.9%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 416.1 Million USD | 67.11% |
| 2022 | 264.6 Million USD | 19.83% |
| 2021 | 218.7 Million USD | -36.55% |
| 2020 | 336.1 Million USD | 44.53% |
| 2019 | 226.6 Million USD | 514.18% |
| 2018 | 56.39 Million USD | 128.08% |
| 2017 | -120.61 Million USD | 14.49% |
| 2016 | -139.59 Million USD | -54.47% |
| 2015 | -87.92 Million USD | -45.71% |
| 2014 | -63.58 Million USD | -28.19% |
| 2013 | -49 Million USD | -2417.73% |
| 2012 | 2.1 Million USD | -106.95% |
| 2011 | 34.61 Million USD | 347.74% |
| 2010 | -13.72 Million USD | 72.29% |
| 2009 | -47.85 Million USD | 32.44% |
| 2008 | -73.97 Million USD | 39.71% |
| 2007 | -193.97 Million USD | -5.92% |
| 2006 | -102.75 Million USD | -586.01% |
| 2005 | -14.97 Million USD | 66.8% |
| 2004 | -45.25 Million USD | 38.35% |
| 2003 | -55.09 Million USD | 27.35% |
| 2002 | -100.51 Million USD | -141.79% |
| 2001 | -41.23 Million USD | -20.93% |
| 2000 | -33.4 Million USD | -91.39% |
| 1999 | -17.8 Million USD | -445.45% |
| 1998 | -10.7 Million USD | -6.45% |
| 1997 | 1.8 Million USD | -720.0% |
| 1996 | 3.9 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 111.5 Million USD | -28.53% |
| 2024 Q2 | 155.2 Million USD | 39.19% |
| 2024 Q3 | 191.3 Million USD | 23.26% |
| 2023 Q1 | 29.7 Million USD | -71.28% |
| 2023 Q4 | 156 Million USD | 10.48% |
| 2023 FY | - USD | 67.11% |
| 2023 Q3 | 141.2 Million USD | 91.85% |
| 2023 Q2 | 73.6 Million USD | 147.81% |
| 2022 Q4 | 103.4 Million USD | 12.64% |
| 2022 FY | - USD | 19.83% |
| 2022 Q2 | 58.6 Million USD | 815.63% |
| 2022 Q3 | 91.8 Million USD | 56.66% |
| 2022 Q1 | 6.4 Million USD | -90.0% |
| 2021 Q1 | 34 Million USD | -52.65% |
| 2021 Q4 | 64 Million USD | 35.31% |
| 2021 Q3 | 47.3 Million USD | -32.81% |
| 2021 Q2 | 70.4 Million USD | 107.06% |
| 2021 FY | - USD | -36.55% |
| 2020 Q2 | 124.7 Million USD | 104.43% |
| 2020 Q4 | 71.8 Million USD | -3.23% |
| 2020 FY | - USD | 44.53% |
| 2020 Q1 | 61 Million USD | -28.24% |
| 2020 Q3 | 74.2 Million USD | -40.5% |
| 2019 Q2 | 41.24 Million USD | 202.18% |
| 2019 FY | - USD | 514.18% |
| 2019 Q1 | 13.65 Million USD | -37.59% |
| 2019 Q3 | 92.1 Million USD | 123.31% |
| 2019 Q4 | 85 Million USD | -7.72% |
| 2018 FY | - USD | 128.08% |
| 2018 Q3 | 55.4 Million USD | 5817.54% |
| 2018 Q4 | 21.87 Million USD | -60.52% |
| 2018 Q1 | -36.66 Million USD | -410.5% |
| 2018 Q2 | -969 Thousand USD | 97.36% |
| 2017 Q2 | -56.67 Million USD | 30.07% |
| 2017 Q4 | 11.8 Million USD | 319.5% |
| 2017 FY | - USD | 14.49% |
| 2017 Q3 | -5.37 Million USD | 90.51% |
| 2017 Q1 | -81.04 Million USD | -69.45% |
| 2016 Q3 | -39.57 Million USD | 8.07% |
| 2016 Q1 | -22.17 Million USD | 31.07% |
| 2016 Q2 | -43.05 Million USD | -94.16% |
| 2016 FY | - USD | -54.47% |
| 2016 Q4 | -47.83 Million USD | -20.85% |
| 2015 Q2 | -26.4 Million USD | -744.45% |
| 2015 Q4 | -32.17 Million USD | 13.08% |
| 2015 Q1 | -3.12 Million USD | 85.44% |
| 2015 FY | - USD | -45.71% |
| 2015 Q3 | -37 Million USD | -40.15% |
| 2014 Q3 | -17.83 Million USD | -17.9% |
| 2014 FY | - USD | -28.19% |
| 2014 Q4 | -21.47 Million USD | -20.39% |
| 2014 Q2 | -15.13 Million USD | -11.92% |
| 2014 Q1 | -13.51 Million USD | -9.0% |
| 2013 FY | - USD | -2417.73% |
| 2013 Q4 | -12.4 Million USD | 2.48% |
| 2013 Q3 | -12.71 Million USD | 9.72% |
| 2013 Q2 | -14.08 Million USD | -2.85% |
| 2013 Q1 | -13.69 Million USD | -278.38% |
| 2012 Q3 | -4.68 Million USD | -123.75% |
| 2012 Q4 | 7.67 Million USD | 263.98% |
| 2012 FY | - USD | -106.95% |
| 2012 Q2 | -2.09 Million USD | 17.79% |
| 2012 Q1 | -2.54 Million USD | -763.05% |
| 2011 Q3 | 29.34 Million USD | 7873.37% |
| 2011 Q4 | -295 Thousand USD | -101.01% |
| 2011 FY | - USD | 347.74% |
| 2011 Q1 | 1.23 Million USD | 297.13% |
| 2011 Q2 | 368 Thousand USD | -70.23% |
| 2010 Q4 | -627 Thousand USD | -132.04% |
| 2010 Q3 | 1.95 Million USD | 130.63% |
| 2010 FY | - USD | 72.29% |
| 2010 Q2 | -6.39 Million USD | 40.31% |
| 2010 Q1 | -10.7 Million USD | -16.91% |
| 2009 Q1 | -7.6 Million USD | 73.91% |
| 2009 FY | - USD | 32.44% |
| 2009 Q3 | -9.54 Million USD | 31.63% |
| 2009 Q4 | -9.15 Million USD | 4.06% |
| 2009 Q2 | -13.96 Million USD | -83.6% |
| 2008 Q2 | -18.11 Million USD | 3.09% |
| 2008 Q4 | -29.14 Million USD | -112.19% |
| 2008 FY | - USD | 39.71% |
| 2008 Q1 | -18.69 Million USD | 85.21% |
| 2008 Q3 | -13.73 Million USD | 24.19% |
| 2007 FY | - USD | -5.92% |
| 2007 Q1 | -24.71 Million USD | -80.6% |
| 2007 Q4 | -126.42 Million USD | -375.03% |
| 2007 Q3 | -26.61 Million USD | -6.11% |
| 2007 Q2 | -25.08 Million USD | -1.49% |
| 2006 Q2 | -26.57 Million USD | -6.6% |
| 2006 Q4 | -13.68 Million USD | 63.11% |
| 2006 FY | - USD | -586.01% |
| 2006 Q3 | -37.09 Million USD | -39.58% |
| 2006 Q1 | -24.92 Million USD | -13.36% |
| 2005 FY | - USD | 66.8% |
| 2005 Q3 | 27.69 Million USD | 841.19% |
| 2005 Q1 | -16.9 Million USD | 9.94% |
| 2005 Q2 | -3.73 Million USD | 77.9% |
| 2005 Q4 | -21.99 Million USD | -179.42% |
| 2004 FY | - USD | 38.35% |
| 2004 Q1 | -13.48 Million USD | 60.95% |
| 2004 Q2 | -11.92 Million USD | 11.62% |
| 2004 Q3 | -941 Thousand USD | 92.11% |
| 2004 Q4 | -18.77 Million USD | -1894.69% |
| 2003 Q2 | -11.48 Million USD | 20.62% |
| 2003 FY | - USD | 27.35% |
| 2003 Q3 | -12.55 Million USD | -9.0% |
| 2003 Q4 | -16.57 Million USD | -174.65% |
| 2003 Q1 | -14.48 Million USD | 64.03% |
| 2002 Q3 | -21.71 Million USD | -1.44% |
| 2002 FY | - USD | -141.79% |
| 2002 Q4 | -40.36 Million USD | -86.17% |
| 2002 Q2 | -21.31 Million USD | -24.13% |
| 2002 Q1 | -17.12 Million USD | -17.52% |
| 2001 Q2 | -14.95 Million USD | -11.78% |
| 2001 Q3 | 1.88 Million USD | 111.48% |
| 2001 FY | - USD | -20.93% |
| 2001 Q1 | -13.48 Million USD | -25.05% |
| 2001 Q4 | -14.67 Million USD | -942.33% |
| 2000 FY | - USD | -91.39% |
| 2000 Q2 | -6.84 Million USD | -19.63% |
| 2000 Q4 | -10.73 Million USD | -15.39% |
| 2000 Q3 | -9.12 Million USD | -23.36% |
| 2000 Q1 | -6.7 Million USD | -30.04% |
| 1999 Q1 | -3.9 Million USD | -174.58% |
| 1999 Q2 | -4.89 Million USD | -31.82% |
| 1999 Q3 | -4.5 Million USD | 22.41% |
| 1999 FY | - USD | -445.45% |
| 1999 Q4 | -4.4 Million USD | -8.89% |
| 1998 Q2 | -3 Million USD | 115.15% |
| 1998 Q1 | -2 Million USD | -50.0% |
| 1998 FY | - USD | -6.45% |
| 1998 Q4 | -200 Thousand USD | 193.65% |
| 1998 Q3 | -2.6 Million USD | -1360.0% |
| 1997 Q1 | 3.4 Million USD | 0.0% |
| 1997 Q3 | -100 Thousand USD | 12.5% |
| 1997 Q4 | -900 Thousand USD | -57.14% |
| 1997 FY | - USD | -720.0% |
| 1997 Q2 | -500 Thousand USD | -169.57% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q2 | 1.5 Million USD | 0.0% |
| 1996 Q3 | -1.2 Million USD | -340.0% |
| 1996 Q4 | 3.6 Million USD | 195.83% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 377.2% |
| Theratechnologies Inc. | -10.31 Million USD | 4134.792% |
| Safety Shot Inc | -12.18 Million USD | 3514.803% |
| Cosmos Health Inc. | -17.06 Million USD | 2538.782% |
| Cronos Group Inc. | -72.14 Million USD | 676.723% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 144.99% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 1253.207% |
| Organogenesis Holdings Inc. | 36.03 Million USD | -1054.839% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 13042.179% |
| ProPhase Labs, Inc. | -14.82 Million USD | 2906.367% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 9295.58% |
| Dynavax Technologies Corporation | 9.66 Million USD | -4204.78% |
| Radius Health, Inc. | 38.31 Million USD | -986.139% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 17798.776% |
| Alvotech | -484.86 Million USD | 185.818% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 10980.087% |
| Alpha Teknova, Inc. | -25.53 Million USD | 1729.273% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 361.94% |
| SCYNEXIS, Inc. | 73.47 Million USD | -466.284% |
| Harrow Health, Inc. | 9.72 Million USD | -4179.543% |
| Biofrontera Inc. | -18.45 Million USD | 2354.918% |
| DURECT Corporation | -24.68 Million USD | 1785.707% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -323.46% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | -280.626% |
| OptiNose, Inc. | -15.55 Million USD | 2775.368% |
| RedHill Biopharma Ltd. | 26.26 Million USD | -1484.169% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -35103.046% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 58635.556% |
| SIGA Technologies, Inc. | 84.15 Million USD | -394.419% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -51143.842% |
| Shineco, Inc. | -26.55 Million USD | 1667.001% |
| Phibro Animal Health Corporation | 84.6 Million USD | -391.803% |
| Procaps Group S.A. | 104.02 Million USD | -299.992% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 5052.982% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 11602.012% |
| Viatris Inc. | 3.51 Billion USD | 88.167% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 10980.087% |
| Rockwell Medical, Inc. | -4.69 Million USD | 8964.508% |
| Incannex Healthcare Limited | -18.5 Million USD | 2348.703% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 41216.601% |
| Tilray Brands, Inc. | -72.84 Million USD | 671.229% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | -34.954% |
| PetIQ, Inc. | 81.48 Million USD | -410.64% |
| Silver Spike Investment Corp. | 7.34 Million USD | -5568.852% |
| Journey Medical Corporation | 1.92 Million USD | -21560.593% |
| Alimera Sciences, Inc. | 7.27 Million USD | -5618.802% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 9979.22% |
| Assertio Holdings, Inc. | -222.44 Million USD | 287.056% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 10526.875% |
| Embecta Corp. | 245.4 Million USD | -69.56% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 2177.303% |
| Procaps Group, S.A. | 104.02 Million USD | -299.992% |
| PainReform Ltd. | -9.56 Million USD | 4448.417% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 379.028% |
| Hempacco Co., Inc. | -12.77 Million USD | 3357.584% |
| Talphera, Inc. | -9.84 Million USD | 4327.799% |
| Pacira BioSciences, Inc. | 162.89 Million USD | -155.437% |
| Alvotech | -484.86 Million USD | 185.818% |
| Lantheus Holdings, Inc. | 491 Million USD | 15.255% |
| Kamada Ltd. | 21.53 Million USD | -1832.293% |
| Indivior PLC | 66 Million USD | -530.455% |
| Currenc Group, Inc. | -1.9 Million USD | 21993.386% |
| Evoke Pharma, Inc. | -7.29 Million USD | 5806.023% |
| Flora Growth Corp. | -45.87 Million USD | 1007.129% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 2177.303% |
| Evolus, Inc. | -41.81 Million USD | 1095.216% |
| HUTCHMED (China) Limited | 25.52 Million USD | -1529.975% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | -72.324% |
| Akanda Corp. | -27.73 Million USD | 1600.233% |